Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mammon who wrote (11164)	4/23/2012 3:19:35 PM
From: Mammon	1 Recommendation Read Replies (2) \| Respond to of 13111

okay, I'm going to start our new take on this message board. I would like to discuss whether pvct should pursue a deal for pv10 before starting the phase III trials. They have the money lined up from Lincoln Park, but would it be better to borrow money and take the drug further through the process, or make a deal. I guess my thoughts are that a deal or sale might allow the drug to be tested in more clinical trials for more indications, thus jumpstarting the drug's marketing. I worry a little that oncovax being further in the drug process and already launched will hurt pvct when it's launched. Does anyone have any thoughts on any of this? Also, does the thought of the possibility of accelerated approval, given the ongoing moffitt studies, throw a wrench in the process?